EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States

Savak Teymoorian, E Randy Craven iD, Lannhi Nguyen, Erica Werts

Clinical Ophthalmology · 2024-01 · Volume 18 · 187-199

DOI: 10.2147/opth.s445005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ophthalmology, 2024-01. Verfasst von Savak Teymoorian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Eye Associates, Laguna Hills, CA, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

A sustained-release, biodegradable, intracameral 10-µg bimatoprost implant (Durysta) is approved for single administration per eye to lower intraocular pressure (IOP) in open-angle glaucoma (OAG) and ocular hypertension (OHT). The purpose of this study was to evaluate the IOP-lowering effectiveness and safety of a single implant administration per eye in patients with OAG or OHT in a real-world clinical setting.

Methods

This was a retrospective, single-site study involving 105 consecutive adult patients with OAG or OHT treated with the bimatoprost implant in 1 or both eyes in routine clinical practice. Available medical records of the patients for 12 months or longer after the initial implant administration were reviewed, and data including IOP, IOP-lowering medication and procedure use, and safety outcomes were collected and analyzed. The analysis used ranges of follow-up because of the real-world setting.

Results

The study included 197 eyes (85.3% diagnosed with OAG, 94.9% pseudophakic, and 83.8% with angle grade 4). IOP reduction was observed through 1 year after the bimatoprost implant administration. Mean IOP was 16.6 mmHg at baseline and 13.3 mmHg at 11-13 months, with the mean number of topical IOP-lowering medications used reduced from 1.4 at baseline to 0.2 at 11-13 months. IOP and IOP-lowering medication use were similarly reduced in eyes treated with both selective laser trabeculoplasty (SLT) and bimatoprost implant (including 66 eyes with their last SLT before implant administration and 28 eyes with their last SLT after implant administration). There were no cases of treatment-emergent corneal edema after bimatoprost implant administration, and no eye required implant removal.

Conclusion

A single bimatoprost implant administration safely and effectively reduced IOP for up to 1 year and decreased the need for topical IOP-lowering medications in eyes with OAG or OHT with or without previous or subsequent SLT.

Schlagwörter

Stichwörter der Autor:innen

biodegradable implantdrug delivery systemintraocular injectionprostaglandin analog

Autor:innen und Institutionen

  • Harvard Eye Associates, Laguna Hills, CA, USA.
  • Allergan, an AbbVie company, Irvine, CA, USA.

ORCID-Profile: E Randy Craven

Zitieren

APA

Teymoorian, S., Craven, E. R., Nguyen, L., & Werts, E. (2024). Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States. Clinical Ophthalmology, Volume 18, 187-199. https://doi.org/10.2147/opth.s445005

Vancouver

Teymoorian S, Craven ER, Nguyen L, Werts E. Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States. Clinical Ophthalmology. 2024;Volume 18:187-199. doi:10.2147/opth.s445005

BibTeX
@article{Teymoorian2024,
  author = {Teymoorian, Savak and Craven, E Randy and Nguyen, Lannhi and Werts, Erica},
  title = {Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States},
  journal = {Clinical Ophthalmology},
  year = {2024},
  volume = {Volume 18},
  pages = {187--199},
  doi = {10.2147/opth.s445005}
}
Kostenlos starten →